Patient characteristics
| Characteristic . | No TBI (n = 252) . | TBI (n = 422) . | P . | |
|---|---|---|---|---|
| Age, median (IQR), y | 49 (40-55) | 45 (33-56) | <.01 | |
| Female sex | 88 (35) | 187 (44) | .02 | |
| Underlying disease | <.01 | |||
| Acute leukemia | 53 (21) | 335 (79) | ||
| MDS/MPN | 51 (20) | 52 (12) | ||
| CLL/lymphoma | 95 (38) | 26 (6) | ||
| CML | 43 (17) | 9 (2) | ||
| Other* | 10 (4) | 0 (0) | ||
| Donor | <.01 | |||
| Matched related | 165 (65) | 175 (41) | ||
| MUD | 63 (25) | 181 (43) | ||
| MMUD | 17 (7) | 64 (15) | ||
| Haploidentical | 7 (3) | 2 (1) | ||
| Stem cell source | <.01 | |||
| Peripheral blood | 201 (80) | 394 (93) | ||
| Bone marrow | 51 (20) | 17 (4) | ||
| Umbilical cord | 0 (0) | 11 (3) | ||
| Grades II-IV aGVHD | 54 (21) | 98 (23) | .63 | |
| Moderate to severe cGVHD | 118 (47) | 132 (31) | <.01 | |
| Chemotherapy cycles pre-HCT, median (IQR) | 2 (0-7) | 3 (2-5) | .27 | |
| Localized radiotherapy pre-HCT | 20 (8) | 44 (10) | .34 | |
| Prior malignancy† | 14 (6) | 24 (6) | 1.0 | |
| Characteristic . | No TBI (n = 252) . | TBI (n = 422) . | P . | |
|---|---|---|---|---|
| Age, median (IQR), y | 49 (40-55) | 45 (33-56) | <.01 | |
| Female sex | 88 (35) | 187 (44) | .02 | |
| Underlying disease | <.01 | |||
| Acute leukemia | 53 (21) | 335 (79) | ||
| MDS/MPN | 51 (20) | 52 (12) | ||
| CLL/lymphoma | 95 (38) | 26 (6) | ||
| CML | 43 (17) | 9 (2) | ||
| Other* | 10 (4) | 0 (0) | ||
| Donor | <.01 | |||
| Matched related | 165 (65) | 175 (41) | ||
| MUD | 63 (25) | 181 (43) | ||
| MMUD | 17 (7) | 64 (15) | ||
| Haploidentical | 7 (3) | 2 (1) | ||
| Stem cell source | <.01 | |||
| Peripheral blood | 201 (80) | 394 (93) | ||
| Bone marrow | 51 (20) | 17 (4) | ||
| Umbilical cord | 0 (0) | 11 (3) | ||
| Grades II-IV aGVHD | 54 (21) | 98 (23) | .63 | |
| Moderate to severe cGVHD | 118 (47) | 132 (31) | <.01 | |
| Chemotherapy cycles pre-HCT, median (IQR) | 2 (0-7) | 3 (2-5) | .27 | |
| Localized radiotherapy pre-HCT | 20 (8) | 44 (10) | .34 | |
| Prior malignancy† | 14 (6) | 24 (6) | 1.0 | |
Data are presented as no. (%) unless otherwise indicated. CML, chronic myeloid leukemia; MDS, myelodysplastic syndrome; MMUD, mismatched unrelated donor; MPN, myeloproliferative neoplasm; MUD, matched unrelated donor.
Seven cases of multiple myeloma and 1 each of red cell aplasia, severe aplastic anemia, and erythropoietic porphyria.
A malignancy that occurred prior to the malignancy for which allo-HCT was undertaken.